UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 353

Sortiert nach

Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine

Cell reports (Cambridge), 2020-05, Vol.31 (5), p.107588-107588, Article 107588

2020

Volltextzugriff (PDF)

Dabrafenib in patients with BRAFV600E -positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

The lancet oncology, 2016-05, Vol.17 (5), p.642-650

2016

Volltextzugriff (PDF)

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3

Cell reports (Cambridge), 2014-04, Vol.7 (1), p.86-93

2014

Volltextzugriff (PDF)

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

Journal of thoracic oncology, 2017-02, Vol.12 (2), p.194-207

2017

Volltextzugriff (PDF)

Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients

Cell reports (Cambridge), 2016-07, Vol.16 (3), p.631-643

2016

Volltextzugriff (PDF)

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.404-415

2020

Volltextzugriff (PDF)

Navigating Diagnostic and Treatment Decisions in Non‐Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach

The oncologist (Dayton, Ohio), 2021-02, Vol.26 (2), p.e306-e315

2021

Volltextzugriff (PDF)

A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer

BMC cancer, 2023-03, Vol.23 (1), p.247-247, Article 247

2023

Volltextzugriff (PDF)

Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer

PloS one, 2024-07, Vol.19 (7), p.e0293707

2024

Volltextzugriff (PDF)

Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

Pharmaceutical research, 2022-10, Vol.39 (10), p.2507-2514

2022

Volltextzugriff (PDF)

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer

Cancer discovery, 2014-05, Vol.4 (5), p.606-619

2014

Volltextzugriff (PDF)

Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial

Radiotherapy and oncology, 2015-10, Vol.117 (1), p.44-48

2015

Volltextzugriff (PDF)

Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study

Future oncology (London, England), 2024-07, p.1-11

Smit, Egbert F.

2024

Volltextzugriff (PDF)

Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes

Oncoimmunology, 2023, Vol.12 (1), p.2204745-2204745

2023

Volltextzugriff (PDF)

Silencing Core Spliceosome Sm Gene Expression Induces a Cytotoxic Splicing Switch in the Proteasome Subunit Beta 3 mRNA in Non-Small Cell Lung Cancer Cells

International journal of molecular sciences, 2020-06, Vol.21 (12), p.4192

2020

Volltextzugriff (PDF)

Identification of protein biomarkers for prediction of response to platinum‐based treatment regimens in patients with non‐small cell lung cancer

Molecular oncology, 2024-06, Vol.18 (6), p.1417-1436

2024

Volltextzugriff (PDF)

Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving Immunotherapy

Frontiers in oncology, 2021-03, Vol.11, p.609054-609054

2021

Volltextzugriff (PDF)

Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report

Frontiers in oncology, 2024-01, Vol.13, p.1330468-1330468

2024

Volltextzugriff (PDF)

Author Correction: BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape

NPJ precision oncology, 2024-07, Vol.8 (1), p.142-1, Article 142

2024

Volltextzugriff (PDF)

The efficacy of Life Review Therapy combined with Memory Specificity Training (LRT-MST) targeting cancer patients in palliative care: A randomized controlled trial

PloS one, 2018-05, Vol.13 (5), p.e0197277-e0197277

2018

Volltextzugriff (PDF)

BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape

NPJ precision oncology, 2024-04, Vol.8 (1), p.90-13, Article 90

2024

Volltextzugriff (PDF)

Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy

Cancers, 2021-06, Vol.13 (12), p.3083

2021

Volltextzugriff (PDF)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance

Cancers, 2020-11, Vol.12 (11), p.3322

2020

Volltextzugriff (PDF)

Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography

Clinical cancer research, 2013-08, Vol.19 (15), p.4163-4173

2013

Volltextzugriff (PDF)

Correction: Clonality analysis of pulmonary tumors by genome-wide copy number profiling

PloS one, 2019-11, Vol.14 (11), p.e0225733-e0225733

2019

Volltextzugriff (PDF)

1 – 25 von 353

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(336)
Mit Volltextzugriff
(326)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(165)
Life Sciences & Biomedicine
(164)
Oncology
(118)
Humans
(109)
Lung Cancer
(62)
Lung Neoplasms - Drug Therapy
(51)
Respiratory System
(42)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(40)
Lung Neoplasms - Pathology
(35)
Tumors
(33)
Mutation
(30)
Chemotherapy
(28)
Lung Neoplasms - Genetics
(26)
Non-Small Cell Lung Carcinoma
(26)
Biological And Medical Sciences
(25)
Medical Sciences
(25)
Nsclc
(25)
Carcinoma, Non-Small-Cell Lung - Genetics
(24)
Cancer
(21)
Carcinoma, Non-Small-Cell Lung - Pathology
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine

Dabrafenib in patients with BRAFV600E -positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Navigating Diagnostic and Treatment Decisions in Non‐Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach

A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer

Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer

Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer

Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial

Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study

Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes

Silencing Core Spliceosome Sm Gene Expression Induces a Cytotoxic Splicing Switch in the Proteasome Subunit Beta 3 mRNA in Non-Small Cell Lung Cancer Cells

Identification of protein biomarkers for prediction of response to platinum‐based treatment regimens in patients with non‐small cell lung cancer

Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving Immunotherapy

Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report

Author Correction: BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape

The efficacy of Life Review Therapy combined with Memory Specificity Training (LRT-MST) targeting cancer patients in palliative care: A randomized controlled trial

BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape

Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance

Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography

Correction: Clonality analysis of pulmonary tumors by genome-wide copy number profiling

Aktive Filter

Suchergebnisse filtern